Accelerated Cure Project (ACP) for multiple sclerosis (MS) is set to partner with Quest Diagnostics and the National Multiple Sclerosis Society to commence a study to assess the immune response of MS patients to Covid-19 vaccinations.

Named COVER-MS Sub-Study, the trial is carried out under the iConquerMS People-Powered Research Network initiative of ACP.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study will collect real-world data on the impact of Covid-19 vaccination on MS patients through subject-reported surveys.

The impact of the number and timing of the vaccine doses on antibody levels and duration in MS patients is the goal of the study.

This project will have 300 sub-study subjects from 1600 COVER-MS project volunteers.

For the study, Quest will offer various services including SARS-CoV-2 serological IgG antibody and T-Cell testing for assessing Covid-19 immune response in the subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study will also have a decentralised clinical trial model through which over 2,100 patient service centres from the national network of Quest will allow subjects to give blood samples periodically.

This partnership will offer proof-of-concept for a convenient and economical decentralised biological study model for subjects and researchers.

The model can be used for upcoming real-world research studies which intend to enrol diverse participants geographically, clinically, and demographically.

National MS Society Research executive vice-president Bruce Bebo said: “Understanding the immune response to the Covid-19 vaccine doses in a longer-term study in people with MS will provide tremendous insights into not only optimal vaccine dosing for this population, but it will shed light on how vaccines may affect people with immune disorders or who are taking immunomodulatory therapies.”